13 active not recruiting. 13 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Active not recruiting 13 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) Azetukalner, Placebo - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 450 | 2025-07-08 | 2026-10-15 |
| A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) Placebo, DT120 - Major Depressive Disorder | Phase 3 | Active not recruiting | Definium Therapeutics US, Inc. | 149 | 2025-04-14 | 2026-08-28 |
| An Open-Label Study of Azetukalner in Major Depressive Disorder Azetukalner - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 460 | 2025-03-18 | 2026-10-13 |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Azetukalner, Placebo - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 450 | 2024-12-20 | 2026-10-13 |
| Psilocybin-Assisted Therapy in Treatment-Resistant Depression psilocybin - Refractory Depression, Treatment Resistant Depression | Phase 3 | Active not recruiting | University of North Carolina, Chapel Hill | 20 | 2024-04-19 | 2026-05-06 |
| Improving Outcomes in Depression in Primary Care in a Low Resource Setting Healthy Activity Program (HAP), Antidepressant medication (fluoxetine) - Depression, Depressive Disorder | Phase 3 | Active not recruiting | Harvard Medical School (HMS and HSDM) | 1500 | 2024-03-18 | 2026-05-22 |
| Psilocybin for Major Depressive Disorder (MDD) Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg - Depressive Disorder, Major | Phase 3 | Active not recruiting | Usona Institute | 238 | 2024-03-13 | 2026-10-21 |
| Predictors of Intravenous Ketamine Response in TRD Ketamine, Midazolam - Treatment Resistant Depression, Major Depressive Disorder | Phase 3 | Active not recruiting | Abraham Nunes | 40 | 2024-01-19 | 2026-05-22 |
| Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women MWSH plus Candlelit Care, MWSH - Pregnancy Related, Pregnancy Complications | Phase 2 / Phase 3 | Active not recruiting | Cedars-Sinai Medical Center | 150 | 2023-06-01 | 2026-10-22 |
| Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD Psilocybin - Treatment Resistant Depression | Phase 3 | Active not recruiting | COMPASS Pathways | 572 | 2023-02-14 | 2026-08-10 |
| mHealth Mindfulness Intervention for Pregnant Black and Latina Women at Risk of Postpartum Depression Stress reduction program 'A', Stress reduction program 'B' - Post Partum Depression, Perinatal Depression | Phase 3 | Active not recruiting | Kaiser Permanente | 600 | 2022-06-14 | 2025-08-05 |
| Neurocognitive Effects of FMT in MDD Patients With and Without IBS Fecal Microbiota Transplantation - Major Depressive Disorder, Irritable Bowel Syndrome | Phase 2 / Phase 3 | Active not recruiting | Valerie Taylor | 133 | 2022-04-06 | 2026-03-19 |
| CODEPAD (Collaborative Outcomes of DEpression and Pain Associated With Delivery) Epidural delivery system, Entonox, Meperidine - Depression, Postpartum, Analgesia, Obstetrical | Phase 2 / Phase 3 | Active not recruiting | KK Women's and Children's Hospital | 881 | 2017-06-15 | 2026-08-06 |
Depression (7) · Depressive Disorder, Major (7) · Depression, Postpartum (3) · Depressive Disorder, Treatment-Resistant (3) · Agnosia (1) · Anxiety Disorders (1) · Bipolar Disorder (1) · Inflammation (1) · Irritable Bowel Syndrome (1) · Pregnancy Complications (1) · Racism (1) · Stress, Psychological (1)
Mental Disorders (13) · Mood Disorders (13) · Behavior (7) · Behavioral Symptoms (7) · Female Urogenital Diseases and Pregnancy Complications (3) · Puerperal Disorders (3) · Urogenital Diseases (3) · Pathological Conditions, Signs and Symptoms (2) · Pregnancy Complications (2) · Bipolar and Related Disorders (1) · Colonic Diseases (1) · Colonic Diseases, Functional (1) · Digestive System Diseases (1) · Gastrointestinal Diseases (1)
Psilocybin (3) · XEN1101 (2) · Antidepressive Agents (1) · Entonox (1) · Fecal Microbiota Transplantation (1) · Fentanyl (1) · Fluoxetine (1) · Ketamine (1) · Meperidine (1) · Midazolam (1) · Nitrous Oxide (1) · Psychiatric Rehabilitation (1) · Remifentanil (1) · Ropivacaine (1) · microcrystalline cellulose (1)
Xenon Pharmaceuticals Inc. (3) · Abraham Nunes (1) · COMPASS Pathways (1) · Cedars-Sinai Medical Center (1) · Definium Therapeutics US, Inc. (1) · Harvard Medical School (HMS and HSDM) (1) · KK Women's and Children's Hospital (1) · Kaiser Permanente (1) · University of North Carolina, Chapel Hill (1) · Usona Institute (1) · Valerie Taylor (1)
United States (9) · Canada (3) · Poland (3) · Finland (2) · Germany (2) · Spain (2) · Czechia (1) · Denmark (1) · France (1) · India (1) · Ireland (1) · Netherlands (1) · Romania (1) · Singapore (1) · Slovakia (1)
Abraham Nunes, MD PhD MBA FRCPC (1) · Ban Leong Sng, FANZCA (1) · Charles Raison, MD (1) · Robert K McClure, MD (1) · Valerie Taylor, MD, PhD (1) · Vikram Patel, MD (1)
PMID 37491196, PMID 37990597, PMID 39732915, PMID 39804360, PMID 40113655, PMID 40470239, PMID 40739549, PMID 40935422, PMID 42049811, PMID 42092800, PMID 42314868
R01MH121632 (1), R21MD017396 (1)